Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation
- Resource Type
- Article
- Source
- In
Multiple Sclerosis and Related Disorders September 2021 - Subject
- Language
- ISSN
- 2211-0348